AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a $69.00 target price by stock analysts at Robert W. Baird in a research report issued to clients and investors on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Robert W. Baird’s target price points to a potential downside of 2.00% from the stock’s current price.

Several other research firms also recently issued reports on ANAB. JMP Securities upped their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday. Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. Credit Suisse Group upped their price objective on AnaptysBio from $38.00 to $85.00 in a research note on Tuesday. Finally, Royal Bank Of Canada began coverage on shares of AnaptysBio in a research report on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $59.14.

AnaptysBio (NASDAQ ANAB) traded down 1.08% during midday trading on Wednesday, reaching $69.65. 584,544 shares of the company’s stock traded hands. The stock has a 50-day moving average of $35.88 and a 200 day moving average of $35.88. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $74.00. The company’s market cap is $1.42 billion.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $3.45 million. On average, analysts anticipate that AnaptysBio will post ($1.98) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/anaptysbios-anab-positive-rating-reaffirmed-at-robert-w-baird.html.

In other AnaptysBio news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the sale, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 in the last three months.

A number of large investors have recently added to or reduced their stakes in ANAB. Bank of New York Mellon Corp acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $373,000. JPMorgan Chase & Co. acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $3,851,000. TIAA CREF Investment Management LLC acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $227,000. MARSHALL WACE ASIA Ltd acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $6,924,000. Finally, Marshall Wace North America L.P. acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $6,924,000. 71.35% of the stock is owned by institutional investors and hedge funds.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.